Wynik wyszukiwania w bazie Polska Bibliografia Lekarska GBL

Zapytanie: SZMIGIERO
Liczba odnalezionych rekordów: 1



Przejście do opcji zmiany formatu | Wyświetlenie wyników w wersji do druku
1/1

Tytuł oryginału: Anthracyclines potentiate activity against murine leukemias L 1210 and P388 in vivo and in vitro.
Autorzy: Szmigielska-Kapłon Anna, Ciesielska Ewa, Szmigiero Leszek, Robak Tadusz
Źródło: Eur. J. Haematol. 2002: 68 (6) s.370-375, il., tab., bibliogr. 37 poz.
Sygnatura GBL: 304,912

Hasła klasyfikacyjne GBL:
  • farmacja
  • hematologia
  • onkologia

    Typ dokumentu:
  • praca doświadczalna
  • praca opublikowana za granicą
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • zwierzęta
  • myszy

    Streszczenie angielskie: Abstract: The interactions of 2-chlorodeoxyadenosine (2-CdA, cladribine) and three anthracyclines: doxorubicin (DOX), idarubicin (IDA) and mitoxantrone (MIT) were evaluated on murine leukemias P 388 adn L 1210. Prolongation of survival time of animals receiving drugs in combination compared to mice tereated with drugs in monotherapy was tested. We have also evaluated interactions of the cytostatics on murine leukemias in vitro by measuring their inhibitory effects on P 388 and L 1210 cell proliferation. We have observed a synergistic effect of MIT and IDA in combination with 2-CdA on P 388 leukemia resulting in an increase of life span (ILS) = 226 p.c in case of MIT + 2-CdA and ILS = 126 p.c. in the case of IDA + 2-CdA, whereas 2-CdA used as a sole drug resulted in an ILS = 47 p.c. The survival time of animals inoculated with P 388 leukemic cells and treated with DOX + 2-CdA was similar to ILS gained by DOX monotherapy (178 p.c. and 200 p.c. respectively). The mice bearing L 1210 leukemia receiving combined chamotherapy lived significantly longer than the animals on single agent regiments. The animals treated with schedule 2-CdA + MIT lived significantly longer (P = 0.004) as compard to the groups receiving drugs in monotherapy (ILS of 2-CdA + MIT group = 60 p.c., ILS of MIT groups 33 p.c., and 2-CdA group 33 p.c.). Finally, combination of DOX or IDA with 2-CdA resulted in ILS = 73 p.c. (2-CdA + DOX regimen), and ILS = 60 p.c. in case of 2-CdA + IDA regimen, which is significantly higher than ILS gained on monotherapy schedules. In vitro tests revealed that all tested anthracyclines enhance the antiproliferative activity of 2-CdA against L 1210 and P 388 leukemic cells (p 0.05)...

    stosując format: